Good Worldwide Launches Leaps.org to Rebuild Public Trust in Science and Journalism
Kira Peikoff was the editor-in-chief of Leaps.org from 2017 to 2021. As a journalist, her work has appeared in The New York Times, Newsweek, Nautilus, Popular Mechanics, The New York Academy of Sciences, and other outlets. She is also the author of four suspense novels that explore controversial issues arising from scientific innovation: Living Proof, No Time to Die, Die Again Tomorrow, and Mother Knows Best. Peikoff holds a B.A. in Journalism from New York University and an M.S. in Bioethics from Columbia University. She lives in New Jersey with her husband and two young sons. Follow her on Twitter @KiraPeikoff.

MARCH 15, 2021 -- LeapsMag, the award-winning online magazine created to encourage public discussion about scientific innovation, re-emerges today as Leaps.org, a non- profit media initiative within the Good Worldwide ecosystem, dedicated to rebuilding public trust in science as a force for good and fostering dialogue about the ethical implications of new breakthroughs. Leaps.org's news and commentary cover a wide range of topics including health and medicine, biotechnology, agriculture, research and development, space exploration, and environmental concerns. Notable contributors and interviewees include neuroscientist Sam Harris, geneticist George Church, Nobel Prize winner Eric Kandel, author Steven Pinker, virologist Angela Rasmussen, and many others.
Science and the media that report on it are facing unprecedented mistrust and suspicion, yet at the same time the COVID-19 pandemic has generated a growing public appetite for accessible information about scientific developments. President Biden has tasked his Surgeon General nominee Vivek Murthy with improving public trust in science as one of his key goals. The Kaiser Family Foundation reported in January that roughly 3 in 10 U.S. health care workers express hesitancy about getting a COVID-19 vaccine. A September 2020 Pew Research Center study found that "majorities across 18 of the 20 publics say that limited public understanding is a problem for coverage of scientific research."
And Edelman Worldwide released global survey results showing that trust in scientists and journalists is down compared with last year, and trust in all information sources is at record lows: "In a world of misinformation and media echo chambers," Edelman stated, "how can we rebuild the trust needed to enable the acceptance of science and innovation to create a brighter future for humanity?"
That's where Leaps.org comes in. The original platform was launched by science writer Kira Peikoff in 2017 as an editorially independent outlet for high-quality journalism and commentary, with financial support from Leaps by Bayer, the impact investment unit of Bayer that invests in paradigm-shifting technologies. Leaps by Bayer holds the conviction that responsible innovation requires broad public engagement on a neutral platform that is free of sponsor bias.
Leaps.org's transition to becoming a non-profit media outlet underscores the publication's guiding principle: total editorial independence. Editor-in-Chief Peikoff ensures that funders have no influence over the content published, including no veto power or advance viewing. She will be expanding key partnerships, special events, and philanthropic projects. "In light of the magnified confusion and suspicion raised by the pandemic, there's never been a more important time for science and media to join together," said Peikoff. "We need to highlight the key role of scientific progress in securing society's future while aggressively countering misinformation and breaking down barriers to inclusive discussion. Leaps.org accomplishes these goals through accessible and accurate storytelling, using the highest caliber sources and rigorous fact-checking." Because Leaps.org is not reliant on a revenue-generating model, its journalism is not tied to conventional performance-driven metrics.
"Scientific progress could change the world for the better, but advances will only have impact if people understand the benefits and feel empowered to ask questions. Stimulating this dialogue has never been more important," said Dr. Jürgen Eckhardt who heads up Leaps by Bayer. "We applaud the evolution of Leaps.org into a non-profit initiative that can realize its mission on a larger scale."
"Right now, a healthy relationship with science is vital to address our biggest challenges – from COVID-19 to climate change. It's an honor to be part of the fast-growing, award-winning Leaps.org platform to help science and society thrive together," said GOOD Worldwide Co- Founder and CEO Max Schorr.
As part of the transition, Leaps.org recently launched a new monthly podcast series, "Making Sense of Science," with the first episode featuring NYU medical bioethicist Dr. Arthur Caplan. On March 11, Leaps.org co-hosted "COVID Vaccines and the Return to Life: Part 1" with the Aspen Institute Science & Society Program and the Sabin–Aspen Vaccine Science & Policy Group, the first of a four-part series that will run throughout 2021. Leaps.org's regular publication schedule features original reporting and commentary from highly sought-after journalists, scientists, academics, and thought leaders. The platform has already achieved significant success in making science compelling to a large audience, achieving close to 6 million page views and 6.2 million engagements on social media in 2020 alone.
About Leaps.org
Leaps.org is a not-for-profit program within the Good Worldwide ecosystem, which also includes Upworthy — a media platform that reaches over 150 million people monthly — whose mission is to share the best of humanity and inspire others to do the same.
Leaps.org publishes award-winning journalism, popularizes scientific progress on social media, and hosts forums about innovation, ethics, and the future of humanity. Leaps.org's projects and activities are supported by a consortium of like-minded partners including the Aspen Institute Science & Society Program, and supporters Leaps by Bayer, the Rita Allen Foundation, the Gordon and Betty Moore Foundation and the Howard Hughes Medical Institute.
Follow Leaps.org @makingsenseofscience on Instagram, @leaps_org on Twitter, and @leaps.org on Facebook and LinkedIn.
Kira Peikoff was the editor-in-chief of Leaps.org from 2017 to 2021. As a journalist, her work has appeared in The New York Times, Newsweek, Nautilus, Popular Mechanics, The New York Academy of Sciences, and other outlets. She is also the author of four suspense novels that explore controversial issues arising from scientific innovation: Living Proof, No Time to Die, Die Again Tomorrow, and Mother Knows Best. Peikoff holds a B.A. in Journalism from New York University and an M.S. in Bioethics from Columbia University. She lives in New Jersey with her husband and two young sons. Follow her on Twitter @KiraPeikoff.
Following the Footsteps of a 105-Year-Old Sprinter
No human has run a distance of 100 meters faster than Usain Bolt’s lightning streak in 2009. He set this record at age 22. But what will Bolt’s time be when he’s 105?
At the Louisiana Senior Games in November 2021, 105-year-old Julia Hawkins of Baton Rouge became the oldest woman to run 100 meters in an official competition, qualifying her for this year's National Senior Games. Perhaps not surprisingly, she was the only competitor in the race for people 105 and older. In this Leaps.org video, I interview Hawkins about her lifestyle habits over the decades. Then I ask Steven Austad, a pioneer in studying the mechanisms of aging, for his scientific insights into how those aspiring to become super-agers might follow in Hawkins' remarkable footsteps.
Following the Footsteps of a 105-Year-Old Sprinter
No human has run a distance of 100 meters faster than Usain Bolt’s lightning streak in 2009. He set this record at age 22. But what will Bolt’s time be when ...Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.
Monkeypox produces more telltale signs than COVID-19. Scientists think that a “ring” vaccination strategy can be used when these signs appear to help with squelching the current outbreak of this disease.
A new virus has emerged and stoked fears of another pandemic: monkeypox. Since May 2022, it has been detected in 29 U.S. states, the District of Columbia, and Puerto Rico among international travelers and their close contacts. On a worldwide scale, as of June 30, there have been 5,323 cases in 52 countries.
The good news: An existing vaccine can go a long way toward preventing a catastrophic outbreak. Because monkeypox is a close relative of smallpox, the same vaccine can be used—and it is about 85 percent effective against the virus, according to the World Health Organization (WHO).
Also on the plus side, monkeypox is less contagious with milder illness than smallpox and, compared to COVID-19, produces more telltale signs. Scientists think that a “ring” vaccination strategy can be used when these signs appear to help with squelching this alarming outbreak.
How it’s transmitted
Monkeypox spreads between people primarily through direct contact with infectious sores, scabs, or bodily fluids. People also can catch it through respiratory secretions during prolonged, face-to-face contact, according to the Centers for Disease Control and Prevention (CDC).
As of June 30, there have been 396 documented monkeypox cases in the U.S., and the CDC has activated its Emergency Operations Center to mobilize additional personnel and resources. The U.S. Department of Health and Human Services is aiming to boost testing capacity and accessibility. No Americans have died from monkeypox during this outbreak but, during the COVID-19 pandemic (February 2020 to date), Africa has documented 12,141 cases and 363 deaths from monkeypox.
Ring vaccination proved effective in curbing the smallpox and Ebola outbreaks. As the monkeypox threat continues to loom, scientists view this as the best vaccine approach.
A person infected with monkeypox typically has symptoms—for instance, fever and chills—in a contagious state, so knowing when to avoid close contact with others makes it easier to curtail than COVID-19.
Advantages of ring vaccination
For this reason, it’s feasible to vaccinate a “ring” of people around the infected individual rather than inoculating large swaths of the population. Ring vaccination proved effective in curbing the smallpox and Ebola outbreaks. As the monkeypox threat continues to loom, scientists view this as the best vaccine approach.
With many infections, “it normally would make sense to everyone to vaccinate more widely,” says Wesley C. Van Voorhis, a professor and director of the Center for Emerging and Re-emerging Infectious Diseases at the University of Washington School of Medicine in Seattle. However, “in this case, ring vaccination may be sufficient to contain the outbreak and also minimize the rare, but potentially serious side effects of the smallpox/monkeypox vaccine.”
There are two licensed smallpox vaccines in the United States: ACAM2000 (live Vaccina virus) and JYNNEOS (live virus non-replicating). The ACAM 2000, Van Voorhis says, is the old smallpox vaccine that, in rare instances, could spread diffusely within the body and cause heart problems, as well as severe rash in people with eczema or serious infection in immunocompromised patients.
To prevent organ damage, the current recommendation would be to use the JYNNEOS vaccine, says Phyllis Kanki, a professor of health sciences in the division of immunology and infectious diseases at the Harvard T.H. Chan School of Public Health. However, according to a report on the CDC’s website, people with immunocompromising conditions could have a higher risk of getting a severe case of monkeypox, despite being vaccinated, and “might be less likely to mount an effective response after any vaccination, including after JYNNEOS.”
In the late 1960s, the ring vaccination strategy became part of the WHO’s mission to globally eradicate smallpox, with the last known natural case described in Somalia in 1977. Ring vaccination can also refer to how a clinical trial is designed, as was the case in 2015, when this approach was used for researching the benefits of an investigational Ebola vaccine in Guinea, Kanki says.
“Since Monkeypox spreads by close contact and we have an effective vaccine, vaccinating high-risk individuals and their contacts may be a good strategy to limit transmission,” she says, adding that privacy is an important ethical principle that comes into play, as people with monkeypox would need to disclose their close contacts so that they could benefit from ring vaccination.
Rapid identification of cases and contacts—along with their cooperation—is essential for ring vaccination to be effective. Although mass vaccination also may work, the risk of infection to most of the population remains low while supply of the JYNNEOS vaccine is limited, says Stanley Deresinski, a clinical professor of medicine in the Infectious Disease Clinic at Stanford University School of Medicine.
Other strategies for preventing transmission
Ideally, the vaccine should be administered within four days of an exposure, but it’s recommended for up to 14 days. The WHO also advocates more widespread vaccination campaigns in the population segment with the most cases so far: men who engage in sex with other men.
The virus appears to be spreading in sexual networks, which differs from what was seen in previously reported outbreaks of monkeypox (outside of Africa), where risk was associated with travel to central or west Africa or various types of contact with individuals or animals from those locales. There is no evidence of transmission by food, but contaminated articles in the environment such as bedding are potential sources of the virus, Deresinski says.
Severe cases of monkeypox can occur, but “transmission of the virus requires close contact,” he says. “There is no evidence of aerosol transmission, as occurs with SARS-CoV-2, although it must be remembered that the smallpox virus, a close relative of monkeypox, was transmitted by aerosol.”
Deresinski points to the fact that in 2003, monkeypox was introduced into the U.S. through imports from Ghana of infected small mammals, such as Gambian giant rats, as pets. They infected prairie dogs, which also were sold as pets and, ultimately, this resulted in 37 confirmed transmissions to humans and 10 probable cases. A CDC investigation identified no cases of human-to-human transmission. Then, in 2021, a traveler flew from Nigeria to Dallas through Atlanta, developing skin lesions several days after arrival. Another CDC investigation yielded 223 contacts, although 85 percent were deemed to be at only minimal risk and the remainder at intermediate risk. No new cases were identified.
How much should we be worried
But how serious of a threat is monkeypox this time around? “Right now, the risk to the general public is very low,” says Scott Roberts, an assistant professor and associate medical director of infection prevention at Yale School of Medicine. “Monkeypox is spread through direct contact with infected skin lesions or through close contact for a prolonged period of time with an infected person. It is much less transmissible than COVID-19.”
The monkeypox incubation period—the time from infection until the onset of symptoms—is typically seven to 14 days but can range from five to 21 days, compared with only three days for the Omicron variant of COVID-19. With such a long incubation, there is a larger window to conduct contact tracing and vaccinate people before symptoms appear, which can prevent infection or lessen the severity.
But symptoms may present atypically or recognition may be delayed. “Ring vaccination works best with 100 percent adherence, and in the absence of a mandate, this is not achievable,” Roberts says.
At the outset of infection, symptoms include fever, chills, and fatigue. Several days later, a rash becomes noticeable, usually beginning on the face and spreading to other parts of the body, he says. The rash starts as flat lesions that raise and develop fluid, similar to manifestations of chickenpox. Once the rash scabs and falls off, a person is no longer contagious.
“It's an uncomfortable infection,” says Van Voorhis, the University of Washington School of Medicine professor. There may be swollen lymph nodes. Sores and rash are often limited to the genitals and areas around the mouth or rectum, suggesting intimate contact as the source of spread.
Symptoms of monkeypox usually last from two to four weeks. The WHO estimated that fatalities range from 3 to 6 percent. Although it’s believed to infect various animal species, including rodents and monkeys in west and central Africa, “the animal reservoir for the virus is unknown,” says Kanki, the Harvard T.H. Chan School of Public Health professor.
Too often, viruses originate in parts of the world that are too poor to grapple with them and may lack the resources to invest in vaccines and treatments. “This disease is endemic in central and west Africa, and it has basically been ignored until it jumped to the north and infected Europeans, Americans, and Canadians,” Van Voorhis says. “We have to do a better job in health care and prevention all over the world. This is the kind of thing that comes back to bite us.”